EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial

Naoki Wada, Mitsuhiro Mizunaga, Noriyuki Abe, Kotona Miyauchi, Shin Kobayashi, Miyu Ohtani, Ryoken Tsunekawa, Masaya Nagabuchi, Shun Morishita, Teppei Ohyama, Satoshi Yamaguchi, Hiromichi Iuchi und 7 weitere

World Journal of Urology · 2024

DOI: 10.1007/s00345-024-04799-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift World Journal of Urology, 2024. Verfasst von Naoki Wada und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan. nwada@asahikawa-med.…. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Urinary Incontinence, Urological Agents, Pyrimidinones. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveUrinary IncontinenceUrological AgentsPyrimidinonesPyrrolidinesThiazolesHumansFemaleCross-Over StudiesProspective StudiesAcetanilidesTreatment OutcomeDouble-Blind MethodAdrenergic beta-3 Receptor Agonists

Stichwörter der Autor:innen

MirabegronOveractive bladderRandomized studyVibegron

Substanzen

mirabegronN-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carbo…AcetanilidesUrological AgentsAdrenergic beta-3 Receptor AgonistsPyrimidinonesPyrrolidinesThiazoles

Autor:innen und Institutionen

  • Department of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan. nwada@asahikawa-med.ac.jp.
  • Nagayama Renal and Urology Clinic, Asahikawa, Japan.
  • Department of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
  • Department of Urology, Kitasaito Hospital, Asahikawa, Japan.
  • Department of Urology, Hokushinkai Megumino Hospital, Eniwa, Japan.
  • Department of Urology, Fukagawa City Hospital, Fukagawa, Japan.

Zitieren

APA

Wada, N., Mizunaga, M., Abe, N., Miyauchi, K., Kobayashi, S., Ohtani, M., Tsunekawa, R., Nagabuchi, M., Morishita, S., Ohyama, T., Yamaguchi, S., Iuchi, H., Noda, T., Saga, Y., Motoya, T., Kawakami, N., Nishihara, M., Numata, A., & Kakizaki, H. (2024). Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World Journal of Urology. https://doi.org/10.1007/s00345-024-04799-4

Vancouver

Wada N, Mizunaga M, Abe N, Miyauchi K, Kobayashi S, Ohtani M, et al. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World Journal of Urology. 2024. doi:10.1007/s00345-024-04799-4

BibTeX
@article{Wada2024,
  author = {Wada, Naoki and Mizunaga, Mitsuhiro and Abe, Noriyuki and Miyauchi, Kotona and Kobayashi, Shin and Ohtani, Miyu and Tsunekawa, Ryoken and Nagabuchi, Masaya and Morishita, Shun and Ohyama, Teppei and Yamaguchi, Satoshi and Iuchi, Hiromichi and Noda, Tsuyoshi and Saga, Yuji and Motoya, Tadasu and Kawakami, Norihiro and Nishihara, Masayuki and Numata, Atsushi and Kakizaki, Hidehiro},
  title = {Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial},
  journal = {World Journal of Urology},
  year = {2024},
  doi = {10.1007/s00345-024-04799-4}
}
Kostenlos starten →